Meta‐analysis of 123I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders
Identifieur interne : 000261 ( Main/Exploration ); précédent : 000260; suivant : 000262Meta‐analysis of 123I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders
Auteurs : Alisha E. King [États-Unis] ; Jim Mintz [États-Unis] ; Donald R. Royall [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-06.
English descriptors
- KwdEn :
Abstract
Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac 123I‐metaiodobenzylguanidine uptake in Lewy body–related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered 123I‐metaiodobenzylguanidine cardiac scintigraphy a “supportive” diagnostic feature, based on limited evidence. We report a meta‐analysis of the literature and an assessment of the utility of 123I‐metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty‐six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed‐effects regression model was used to analyze the delayed mean heart‐to‐mediastinum ratio of 123I‐metaiodobenzylguanidine uptake. 123I‐metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart‐to‐mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. 123I‐metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23659
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Meta‐analysis of 123I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders</title><author><name sortKey="King, Alisha E" sort="King, Alisha E" uniqKey="King A" first="Alisha E." last="King">Alisha E. King</name></author><author><name sortKey="Mintz, Jim" sort="Mintz, Jim" uniqKey="Mintz J" first="Jim" last="Mintz">Jim Mintz</name></author><author><name sortKey="Royall, Donald R" sort="Royall, Donald R" uniqKey="Royall D" first="Donald R." last="Royall">Donald R. Royall</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BA725DD8E9CFB2DBBAA45593106662570E43744D</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23659</idno><idno type="url">https://api.istex.fr/document/BA725DD8E9CFB2DBBAA45593106662570E43744D/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001B25</idno><idno type="wicri:Area/Main/Curation">001863</idno><idno type="wicri:Area/Main/Exploration">000261</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Meta‐analysis of 123I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders</title><author><name sortKey="King, Alisha E" sort="King, Alisha E" uniqKey="King A" first="Alisha E." last="King">Alisha E. King</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Mintz, Jim" sort="Mintz, Jim" uniqKey="Mintz J" first="Jim" last="Mintz">Jim Mintz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Royall, Donald R" sort="Royall, Donald R" uniqKey="Royall D" first="Donald R." last="Royall">Donald R. Royall</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Family & Community Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>South Texas Veterans' Health System Audie L. Murphy Division GRECC, San Antonio, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-06">2011-06</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1218">1218</biblScope><biblScope unit="page" to="1224">1224</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">BA725DD8E9CFB2DBBAA45593106662570E43744D</idno><idno type="DOI">10.1002/mds.23659</idno><idno type="ArticleID">MDS23659</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer's disease</term><term>Parkinson's disease</term><term>dementia with Lewy bodies</term><term>multiple system atrophy</term><term>parasomnias</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac 123I‐metaiodobenzylguanidine uptake in Lewy body–related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered 123I‐metaiodobenzylguanidine cardiac scintigraphy a “supportive” diagnostic feature, based on limited evidence. We report a meta‐analysis of the literature and an assessment of the utility of 123I‐metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty‐six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed‐effects regression model was used to analyze the delayed mean heart‐to‐mediastinum ratio of 123I‐metaiodobenzylguanidine uptake. 123I‐metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart‐to‐mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. 123I‐metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies. © 2011 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="King, Alisha E" sort="King, Alisha E" uniqKey="King A" first="Alisha E." last="King">Alisha E. King</name></region><name sortKey="Mintz, Jim" sort="Mintz, Jim" uniqKey="Mintz J" first="Jim" last="Mintz">Jim Mintz</name><name sortKey="Royall, Donald R" sort="Royall, Donald R" uniqKey="Royall D" first="Donald R." last="Royall">Donald R. Royall</name><name sortKey="Royall, Donald R" sort="Royall, Donald R" uniqKey="Royall D" first="Donald R." last="Royall">Donald R. Royall</name><name sortKey="Royall, Donald R" sort="Royall, Donald R" uniqKey="Royall D" first="Donald R." last="Royall">Donald R. Royall</name><name sortKey="Royall, Donald R" sort="Royall, Donald R" uniqKey="Royall D" first="Donald R." last="Royall">Donald R. Royall</name><name sortKey="Royall, Donald R" sort="Royall, Donald R" uniqKey="Royall D" first="Donald R." last="Royall">Donald R. Royall</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000261 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000261 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:BA725DD8E9CFB2DBBAA45593106662570E43744D
|texte= Meta‐analysis of 123I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders
}}
| This area was generated with Dilib version V0.6.23. |  |